Nadir CA-125 Level Is an Independent Prognostic Factor in Advanced Epithelial Ovarian Cancer

被引:23
作者
Kang, Sokbom [1 ]
Seo, Sang-Soo [1 ]
Park, Sang-Yoon [1 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Branch Uterine Canc, Goyang 411769, South Korea
关键词
ovarian cancer; CA-125; cytoreductive surgery; prognostic factor; progression free survival; GYNECOLOGIC-ONCOLOGY-GROUP; CA125; CONCENTRATION; THERAPY; CHEMOTHERAPY; PACLITAXEL; CARCINOMA; SURVIVAL; PLATINUM; SURGERY; TRIAL;
D O I
10.1002/jso.21258
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of this study was to determine the independency of a nadir CA-125 level as a prognostic factor in patients with advanced epithelial ovarian cancer (EOC). Methods: Among the 153 women with advanced EOC who had surgery in our hospital between January 2001 and June 2007, 121 women underwent retrospective chart review. Results: Sixty-six patients (57.9%) had nadir CA-125 values <= 10 U/ml. The CA-125 levels at the time of diagnosis was associated with the nadir CA-125 (P = 0.018). The median progression-free survival (PFS) in patients with nadir CA-125 levels <= 10 and 10-35 U/ml was 32.4 and 16.8 months, respectively (P = 0.0001). A multivariate Cox hazard model revealed that the nadir CA-125 value and the residual tumor size >= 0.5 cm were independently associated with the PFS (P = 0.001 and 0.014). Within the subgroup who underwent primary debulking surgery, the significant association between the PFS and the nadir CA-125 value was preserved (P = 0.001). Conclusions: The prognostic role of the nadir CA-125 is independent of residual tumor size in the patients with advanced EOC. However, it is still unclear whether maximal surgical effort can affect the nadir CA-125 levels. J. Surg. Oncol. 2009;100:244-247. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 12 条
  • [1] Intraperitoneal therapy for ovarian cancer: A treatment ready for prime time
    Armstrong, Deborah K.
    Brady, Mark F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) : 4531 - 4533
  • [2] Nadir CA125 concentration as a prognostic indicator in ovarian cancer
    Baron, AT
    Maihle, N
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (06): : 288 - 289
  • [3] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    Bristow, RE
    Tomacruz, RS
    Armstrong, DK
    Trimble, EL
    Montz, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1248 - 1259
  • [4] Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
    Crawford, SM
    Peace, J
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (01) : 47 - 50
  • [5] Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study
    De Placido, S
    Scambia, G
    Di Vagno, G
    Naglieri, E
    Lombardi, AV
    Biamonte, R
    Marinaccio, M
    Carteni, G
    Manzione, L
    Febbraro, A
    de Matteis, A
    Gasparini, G
    Valerio, MR
    Danese, S
    Perrone, F
    Lauria, R
    De Laurentiis, M
    Greggi, S
    Gallo, C
    Pignata, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2635 - 2642
  • [6] Cancer statistics, 2005
    Jemal, A
    Murray, T
    Ward, E
    Samuels, A
    Tiwari, RC
    Ghafoor, A
    Feuer, EJ
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) : 10 - 30
  • [7] CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Juretzka, Margrit M.
    Barakat, Richard R.
    Chi, Dennis S.
    Iasonos, Alexia
    Dupont, Jakob
    Abu-Rustum, Nadeem R.
    Poynor, Elizabeth A.
    Aghajanian, Carol
    Spriggs, David
    Hensley, Martee L.
    Sabbatini, Paul
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 176 - 180
  • [8] Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
    Markman, M
    Liu, PY
    Wilczynski, S
    Monk, B
    Copeland, LJ
    Alvarez, RD
    Jiang, C
    Alberts, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2460 - 2465
  • [9] Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
    Markmann, M
    Liu, PY
    Rothenberg, ML
    Monk, BJ
    Brady, M
    Alberts, DS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1454 - 1458
  • [10] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    Ozols, RF
    Bundy, BN
    Greer, BE
    Fowler, JM
    Clarke-Pearson, D
    Burger, RA
    Mannel, RS
    DeGeest, K
    Hartenbach, EM
    Baergen, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200